Crossignal Therapeutics initiates First-in-Patient dosing of CT3001, a first-in-class small molecule GPR35-YAP inhibitor indicated for solid tumors.

Crossignal Therapeutics to present a poster at AACR Annual Meeting 2024 in Session “Late-Breaking Research: Experimental and Molecular Therapeutics 4” titled: Evidence for a role of GPR35 in IDO1-mediated tumor immune escape by regulating Hippo-YAP pathway.

Crossignal Therapeutics to present a poster at AACR Annual Meeting 2024 in Session “Late-Breaking Research: Experimental and Molecular Therapeutics 2” titled: Discovery of CT3021, a novel potent adenosine A2a/A2b/A1 receptor triple antagonist.

Crossignal Therapeutics is awarded by Pharma Tech Outlook “Top 10 Immunotherapy Solutions Providers 2024”, with a cover story article about Crossignal’s novel approach in precision medicine and immuno-oncology drug discovery.

Crossignal Therapeutics received IND clearance by FDA for its First-in-Class TMER1 (aka. GPR35) inhibitor CT3001 to enter clinical phase.